9999999997-16-022936.txt : 20160516 9999999997-16-022936.hdr.sgml : 20160516 20160516141128 ACCESSION NUMBER: 9999999997-16-022936 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 20160516 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 161652657 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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